HCA Healthcare, Inc. $HCA Stake Boosted by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership grew its stake in shares of HCA Healthcare, Inc. (NYSE:HCA) by 11.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,311,112 shares of the company’s stock after acquiring an additional 245,887 shares during the period. HCA Healthcare accounts for 0.6% of Arrowstreet Capital Limited Partnership’s investment portfolio, making the stock its 24th biggest holding. Arrowstreet Capital Limited Partnership’s holdings in HCA Healthcare were worth $1,078,966,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the stock. State Street Corp grew its holdings in shares of HCA Healthcare by 1.0% during the 4th quarter. State Street Corp now owns 7,566,643 shares of the company’s stock valued at $3,532,563,000 after acquiring an additional 76,039 shares in the last quarter. Capital World Investors grew its holdings in shares of HCA Healthcare by 0.8% during the 4th quarter. Capital World Investors now owns 4,999,422 shares of the company’s stock valued at $2,334,040,000 after acquiring an additional 40,086 shares in the last quarter. Geode Capital Management LLC increased its position in HCA Healthcare by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 3,663,705 shares of the company’s stock worth $1,702,738,000 after buying an additional 13,565 shares during the last quarter. Norges Bank acquired a new stake in shares of HCA Healthcare in the fourth quarter worth about $1,262,513,000. Finally, Morgan Stanley lifted its position in shares of HCA Healthcare by 3.0% in the fourth quarter. Morgan Stanley now owns 2,194,522 shares of the company’s stock worth $1,024,535,000 after buying an additional 64,630 shares during the last quarter. 62.73% of the stock is currently owned by hedge funds and other institutional investors.

HCA Healthcare Price Performance

HCA stock opened at $387.25 on Friday. HCA Healthcare, Inc. has a 52-week low of $330.00 and a 52-week high of $556.52. The company has a 50-day moving average of $429.60 and a two-hundred day moving average of $473.48. The stock has a market capitalization of $85.91 billion, a price-to-earnings ratio of 13.32, a price-to-earnings-growth ratio of 1.23 and a beta of 1.12.

HCA Healthcare (NYSE:HCA) last announced its quarterly earnings data on Friday, April 24th. The company reported $7.15 EPS for the quarter, missing analysts’ consensus estimates of $7.19 by ($0.04). The company had revenue of $19.11 billion for the quarter, compared to analyst estimates of $19.09 billion. HCA Healthcare had a net margin of 8.89% and a negative return on equity of 295.93%. The firm’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period in the prior year, the company posted $6.45 EPS. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. Equities analysts expect that HCA Healthcare, Inc. will post 30.07 EPS for the current fiscal year.

HCA Healthcare Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 16th will be given a dividend of $0.78 per share. The ex-dividend date of this dividend is Tuesday, June 16th. This represents a $3.12 dividend on an annualized basis and a dividend yield of 0.8%. HCA Healthcare’s dividend payout ratio is currently 10.73%.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on HCA. Argus reduced their price target on HCA Healthcare from $560.00 to $500.00 and set a “buy” rating for the company in a research report on Monday, May 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of HCA Healthcare in a research report on Wednesday, March 4th. Leerink Partners dropped their price target on shares of HCA Healthcare from $573.00 to $500.00 and set an “outperform” rating on the stock in a research report on Monday, April 27th. Weiss Ratings cut shares of HCA Healthcare from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday. Finally, Royal Bank Of Canada decreased their price target on shares of HCA Healthcare from $593.00 to $534.00 and set an “outperform” rating for the company in a report on Monday, April 27th. Fifteen investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $506.14.

About HCA Healthcare

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.